drugset / Trial / NCT05527821
Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
Phase 2
Unknown
36 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NaSingle-groupOpen-labelTreatment
Summary
An exploratory clinical study of short course radiotherapy combined with surufatinib and sintilimab in the treatment of relapsed and refractory advanced solid tumors
Timeline
- Start
- 2022-09-30
- Primary completion
- 2024-09-30
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Surufatinib | Small molecule | 250 mg | Oral |